Aurania Resources Ltd. (AUIAF)(ARU:CA) – Finds New Epithermal Target: Gold Found In Streams


Aurania Finds New Epithermal Target: Gold Found In Streams

 

Toronto, Ontario, May 04, 2021 – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”) reports on a new epithermal target called Kuripan in its Lost Cities – Cutucu Project (“Project”) in southeastern Ecuador.  Gold has been panned from streams that drain the target area.

The streams where gold was panned drain an area in which silica veinlets that have typical epithermal characteristics, occur in volcanic tuff.  Results from stream sediment sampling show that, in addition to gold and silver, the area is enriched in pathfinder elements such as naturally occurring arsenic and antimony.

Aurania’s Chairman & CEO, Dr. Keith Barron commented, “After focusing on our silver-zinc discovery in the last few press releases, I’m very pleased to report that we have an exciting new target where we’ve been able to pan gold from streams draining an area that has an epithermal signature.  Furthermore, indications from the field are that this is an “intermediate-sulphidation” epithermal system – the same type of mineralization as Lundin Gold’s Fruta del Norte mine 100 kilometres to the south of us in the Cordillera del Condor.”

Geological Details of the Kuripan Target

Gold was panned from streams over an area of approximately 12 square kilometres (Figure 1).  Pan concentrates returned values of up to 1 gram per tonne (“g/t”) and the gold grains have an irregular shape consistent with a local source (Figure 2).  Stream sediment sample results have elevated concentrations of silver, arsenic and antimony (Figure 1), and mercury, molybdenum, selenium and thallium.

The target area lies within a sequence of black shales and siltstones of the Jurassic Santiago Formation.  These strata are extensively silicified in the target area and some chalcedonic silica contains casts of adularia (Figure 2), a key alteration mineral found in low- and intermediate- sulphidation epithermal systems.  Banded chalcedonic veinlets are located in volcanic tuff, which is not an ideal host for epithermal veins because the rock is not sufficiently brittle for intense veining to occur.  The target for well-developed epithermal veins is the thick lavas beneath the area in which gold occurs at surface.

A clay-altered diatreme breccia is located near the target area and near where the adularia casts were found (Figure 1). The diatreme is reminiscent of the lower parts of the maar-diatreme systems at Crunchy Hill and Yawi.

The occurrence of adularia with extensive manganese oxide staining suggests that the mineralized system is an intermediate-sulphidation epithermal.

Next Steps

Soil sampling teams are operating in the Kuripan area – the intention being to define the area from which the gold is being eroded into the streams.  More detailed geological mapping is underway to refine the target with emphasis on the distribution of brittle lavas that lie beneath the target area.

 

Figure 1.  a. Plan view of distribution of gold values in pan concentrate samples in the Kuripan target area.  Also shown is the location of silica with casts of adularia. b. Distribution of silver in stream sediment samples. c. Distribution of naturally occurring arsenic in stream sediment samples. d. Distribution of antimony in stream sediment samples.

 

Figure 2.  a. Field guide panning in the Kuripan target area.  b. Gold grains from one of the sample sites in a wooden pan. c. Chalcedonic silica from a banded vein. d. Casts of weathered-out adularia crystals evident in chalcedonic silica.

Sample Analysis & Quality Assurance / Quality Control (“QAQC”) 

Laboratories: The stream and pan concentrate samples were prepared for analysis at MS Analytical (“MSA”) in Cuenca, Ecuador, and the analyses were done in Vancouver, Canada.

Sample preparation: The pan concentrate samples were jaw-crushed to 10 mesh (crushed material passes through a mesh with apertures of 2 millimetres (“mm”)), from which a one-kilogram sub-sample was taken.  The sub-sample was crushed to a grain size of 0.075mm and a 200-gram (“g”) split was set aside for analysis.

The stream sediment samples were wet-sieved through a 20 mesh (0.84mm) screen in the field and placed in cloth bags so that excess water could drain.  The samples were transported from the field to Aurania’s field office in Macas, Ecuador and batched for delivery to at MSA in Cuenca, for drying and screening at 80 mesh (0.18mm sieve aperture).  The -80 mesh silt was packaged by MSA for analysis.

Analytical procedure:  Approximately 0.25g of pan concentrate pulp or -80# soil underwent four-acid digestion and analysis for 48 elements by ICP-MS.

Stream sediment: a 0.5g split of the -80 mesh fraction of the stream silt underwent digestion with aqua regia and the liquid was analyzed for 48 elements by ICP-MS.

Apart from being analyzed by ICP-MS, gold was also analyzed by fire assay with an ICP-AES finish.

QAQC: Aurania personnel inserted a certified standard pulp sample, alternating with a field blank, at approximate 20 sample intervals in all sample batches. Aurania’s analysis of results from its independent QAQC samples showed the batches reported on above, lie within acceptable limits.  In addition, the labs reported that the analyses had passed their internal QAQC tests.

Qualified Person

The geological information contained in this news release has been verified and approved by Jean-Paul Pallier, MSc.  Mr. Pallier is a designated EurGeol by the European Federation of Geologists and a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

[email protected]

Dr. Richard Spencer

President

Aurania Resources Ltd.

(416) 367-3200

[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

QuickChek – May 4, 2021



Aurania Finds New Epithermal Target: Gold Found In Streams

Aurania Resources reported on a new epithermal target called Kuripan in its Lost Cities – Cutucu Project in southeastern Ecuador

Research, News & Market Data on Aurania Resources

Watch recent presentation from NobleCon17



Cocrystal up 100% on plans of a new antiviral drug development

Cocrystal has made progress on its Covid-19 antiviral drug candidates and plans to expand development

Research, News & Market Data on Cocrystal Pharma

Watch recent presentation from NobleCon17



Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer

Research, News & Market Data on Genprex

Watch recent presentation from NobleCon17



Comtech Telecommunications Corp. Awarded $6.5 Million of Funding for Cyber Training Solutions

Comtech Telecommunications announced that during its third quarter of fiscal 2021, its Government Solutions segment was awarded an additional $6.5 million of funding for its Joint Cyber Analysis Course Training solutions

Research, News & Market Data on Comtech

Watch recent presentation from NobleCon17



ACCO Brands Corporation Declares Quarterly Dividend

ACCO Brands announced that its board of directors has declared a quarterly cash dividend of $0.065 per share

Research, News & Market Data on ACCO Brands

Watch recent presentation from NobleCon17



electroCore, Inc. Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire

electroCore announced the U.S. Department of Veterans Affairs is starting an investigator-initiated study of the use of gammaCore Sapphire™ non-invasive vagus nerve stimulation (nVNS) for the treatment of post-traumatic headache

Research, News & Market Data on electroCore



Lineage Cell Therapeutics To Report First Quarter 2021 Financial Results And Provide Business Update On May 13, 2021

Lineage Cell Therapeutics announced that it will report its first quarter 2021 financial and operating results on Thursday, May 13, 2021

Research, News & Market Data on Lineage Cell Therapeutics

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

Release – Aurania Resources Ltd. (AUIAF)(ARU:CA) – Finds New Epithermal Target: Gold Found In Streams


Aurania Finds New Epithermal Target: Gold Found In Streams

 

Toronto, Ontario, May 04, 2021 – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”) reports on a new epithermal target called Kuripan in its Lost Cities – Cutucu Project (“Project”) in southeastern Ecuador.  Gold has been panned from streams that drain the target area.

The streams where gold was panned drain an area in which silica veinlets that have typical epithermal characteristics, occur in volcanic tuff.  Results from stream sediment sampling show that, in addition to gold and silver, the area is enriched in pathfinder elements such as naturally occurring arsenic and antimony.

Aurania’s Chairman & CEO, Dr. Keith Barron commented, “After focusing on our silver-zinc discovery in the last few press releases, I’m very pleased to report that we have an exciting new target where we’ve been able to pan gold from streams draining an area that has an epithermal signature.  Furthermore, indications from the field are that this is an “intermediate-sulphidation” epithermal system – the same type of mineralization as Lundin Gold’s Fruta del Norte mine 100 kilometres to the south of us in the Cordillera del Condor.”

Geological Details of the Kuripan Target

Gold was panned from streams over an area of approximately 12 square kilometres (Figure 1).  Pan concentrates returned values of up to 1 gram per tonne (“g/t”) and the gold grains have an irregular shape consistent with a local source (Figure 2).  Stream sediment sample results have elevated concentrations of silver, arsenic and antimony (Figure 1), and mercury, molybdenum, selenium and thallium.

The target area lies within a sequence of black shales and siltstones of the Jurassic Santiago Formation.  These strata are extensively silicified in the target area and some chalcedonic silica contains casts of adularia (Figure 2), a key alteration mineral found in low- and intermediate- sulphidation epithermal systems.  Banded chalcedonic veinlets are located in volcanic tuff, which is not an ideal host for epithermal veins because the rock is not sufficiently brittle for intense veining to occur.  The target for well-developed epithermal veins is the thick lavas beneath the area in which gold occurs at surface.

A clay-altered diatreme breccia is located near the target area and near where the adularia casts were found (Figure 1). The diatreme is reminiscent of the lower parts of the maar-diatreme systems at Crunchy Hill and Yawi.

The occurrence of adularia with extensive manganese oxide staining suggests that the mineralized system is an intermediate-sulphidation epithermal.

Next Steps

Soil sampling teams are operating in the Kuripan area – the intention being to define the area from which the gold is being eroded into the streams.  More detailed geological mapping is underway to refine the target with emphasis on the distribution of brittle lavas that lie beneath the target area.

 

Figure 1.  a. Plan view of distribution of gold values in pan concentrate samples in the Kuripan target area.  Also shown is the location of silica with casts of adularia. b. Distribution of silver in stream sediment samples. c. Distribution of naturally occurring arsenic in stream sediment samples. d. Distribution of antimony in stream sediment samples.

 

Figure 2.  a. Field guide panning in the Kuripan target area.  b. Gold grains from one of the sample sites in a wooden pan. c. Chalcedonic silica from a banded vein. d. Casts of weathered-out adularia crystals evident in chalcedonic silica.

Sample Analysis & Quality Assurance / Quality Control (“QAQC”) 

Laboratories: The stream and pan concentrate samples were prepared for analysis at MS Analytical (“MSA”) in Cuenca, Ecuador, and the analyses were done in Vancouver, Canada.

Sample preparation: The pan concentrate samples were jaw-crushed to 10 mesh (crushed material passes through a mesh with apertures of 2 millimetres (“mm”)), from which a one-kilogram sub-sample was taken.  The sub-sample was crushed to a grain size of 0.075mm and a 200-gram (“g”) split was set aside for analysis.

The stream sediment samples were wet-sieved through a 20 mesh (0.84mm) screen in the field and placed in cloth bags so that excess water could drain.  The samples were transported from the field to Aurania’s field office in Macas, Ecuador and batched for delivery to at MSA in Cuenca, for drying and screening at 80 mesh (0.18mm sieve aperture).  The -80 mesh silt was packaged by MSA for analysis.

Analytical procedure:  Approximately 0.25g of pan concentrate pulp or -80# soil underwent four-acid digestion and analysis for 48 elements by ICP-MS.

Stream sediment: a 0.5g split of the -80 mesh fraction of the stream silt underwent digestion with aqua regia and the liquid was analyzed for 48 elements by ICP-MS.

Apart from being analyzed by ICP-MS, gold was also analyzed by fire assay with an ICP-AES finish.

QAQC: Aurania personnel inserted a certified standard pulp sample, alternating with a field blank, at approximate 20 sample intervals in all sample batches. Aurania’s analysis of results from its independent QAQC samples showed the batches reported on above, lie within acceptable limits.  In addition, the labs reported that the analyses had passed their internal QAQC tests.

Qualified Person

The geological information contained in this news release has been verified and approved by Jean-Paul Pallier, MSc.  Mr. Pallier is a designated EurGeol by the European Federation of Geologists and a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

[email protected]

Dr. Richard Spencer

President

Aurania Resources Ltd.

(416) 367-3200

[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

The Russell Index Reconstitution, What to Know


The Annual Russell Index Revision and Dates to Watch

 

The yearly process of recasting the Russell Indexes begins on May 7, 2021, and will be complete by market open on June 26. During the period in between, Russell will rank stocks for additions, for deletions and evaluate the names to make sure they conform overall. The methodology is largely transparent to help smooth the process. Still, Russell index products are used by institutional and retail investors globally, with more than $16 trillion currently benchmarked to them. This includes approximately $9 trillion benchmarked to the Russell US Equity indexes. The trading volume of some companies moving into an index will heighten around the last Friday in June as fund managers seek to maintain level tracking with their index target.  For non-passive investor money, determining which stocks may benefit from moving up to a larger cap index, down to a smaller one, or into or out of the measurements is an annual event with volatility around stocks. There is, of course, the potential for very profitable long and short trades.

Active investors should make themselves aware of the forces at play so they may either get out of the way or become involved by taking positions with those being added or those at the end of their reign within one of the Russell measurements.


COVid-19 Dramatic Valuation
Shifts

The reconstitution mid-year 2021 is going to impact a much larger number of companies than most years. As with everything else related to the financial markets, the price swings will likely be more amplified than normal. That is to say, more companies than normal will move in, out or to another index.

 

The 2021 Russell
US Index Reconstitution Calendar is as Follows:

• Friday, May 7 – “rank day” – Russell US Index membership eligibility for 2021 reconstitution determined from constituent market capitalization at market close.

• June 4 – preliminary US index add & delete lists posted to the FTSE Russell website after 6 PM US eastern time.

• June 11 & 18 – US index add & delete lists (reflecting any updates) posted to the FTSE Russell website after 6 PM US eastern time.

• June 14 – “lockdown” period begins – US index adds & delete lists are considered final • June 25 – Russell Reconstitution is final after the close of the US equity markets.

• June 26 – equity markets open with the newly reconstituted Russell US Indexes.

 

Take-Away

The annual reconstitution is a significant driver of dramatic shifts in some stock prices as portfolio managers have their needs shifted within a very short period of time. Longer-term demand for certain equities is altered as well. Sizable price movements and volatility are expected, especially around the last week in June. In fact, the opening day of the reconstitution is typically one of the highest trading-volume days of the year in US equity markets.

The market event impacts more than $9 trillion of investor assets benchmarked to or invested in products based on the Russell US Indexes. Portfolio managers that are required to track one of these indexes will work to have minimal portfolio slippage away from their benchmark.  The days and weeks from May 7 through the end of June can create opportunities for investors seeking to benefit from price moves, Channelchek will be covering the event as stocks to be added to, or removed from this year’s Russell Reconstitution and other information plays out. Be sure to register to receive Channelchek updates and information.

 

Suggested Reading:

Stock Index Adjustments and Self-Directed Investors

Do Microcap Stocks Provide Better Diversification?



Climbing the “Wall of Worry”

The Correlation between Passive Investing and Underperformance

 

Source:  

FTSE Russell Press Release

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Titan Minerals (TTNF) – March 2021 Quarterly Activities Report


March 2021 Quarterly Activities Report

 

Highlights

  • Diamond drilling results over the Iguana
    and Papayal Prospects received. Diamond  drilling confirms
    widths and grades of the Iguana vein sets reported under the Canadian
    NI 43-101 resource estimate. Better intercepts reported (refer to
    ASX releases dated 3 February and 29 April 2021) include:

    o 4.94m @ 6.28 g/t gold and 16 g/t silver from 82.22m – IGD007
    o 2.28m @ 6.82g/t gold and 88g/t silver from 24.52m – IGD010
    o 2.69m @ 7.54 g/t gold and 38 g/t silver from 125.76m IGD013
    o 3.80m @ 6.92 g/t gold and 30 g/t silver from 117.20m IGD015
    o 8.46m @ 2.23g/t gold and 11g/t silver from 83.60m – IGD016
    o 2.9m @ 20.7g/t gold and 57g/t silver from 49m – TPD005
    o 3.85m @ 3.01g/t gold and 5 g/t silver from 85.8m – TPD008
  • Structural analyses of oriented diamond
    core and 3D modelling for both Iguana and Papayal Prospects
    completed, Resource modelling work progressing concurrent
    with confirmatory drilling activity.
  • Diamond Drilling continues in June
    Quarter on the Cerro Verde Prospect as part of an ongoing 12,000m
    campaign.
  • Re-logging work on over 33,000m of
    archived diamond core from previous drill programmes completed in the
    March quarter. Better Intercepts reported from resampling work (refer to
    ASX release dated 17 February 2021) include:

    o 9.78m @ 0.93 g/t golfd and 10 g/t silver from 3.0m and
    5.9m @ 5.35 g/t gold and 20 g/t silver from 37m and
    25m @ 1.51 g/t gold and 9g/t silver from 66m (CV19-010)

    o 13.9m @ 0.95 g/t gold and 18g/t silver from 24.83m
    Including 2.45m @ 3.01g/t gold and 86g/t silver and
    18.2m @ 0.98 g/t gold and 6 g/t silver from 46m (CV19-012)

    o 4.75m @ 5.65g/t gold and 8 g/t silver from 14.6m (CV19-015)

    o 5.68m @ 1.79 g/t gold and 4 g/t silver from 66.81m (CV19-023)

    o 4.25m @ 6.37g/t gold and 111g/t silver from 56.85m and
    10.8m @ 2.06g/t gold and 10 g/t silver from 89.5m (CV19-028)

Copper Duke geochemistry and geophysical
interpretation results received.

o Geophysics confirms and extends a corridor hosting multiple clusters of intrusive centers

o Multiple extensions to surface expressions of porphyry mineralization and high-grade gold veining located in several areas across the project:
– 11.2m @ 0.98% copper and 4.05m @ 16.4g/t gold
– 26m @ 1.13g/t gold and 0.21% copper

Click here to view full quarterly activities and cashflow report

 

Click here to view annual report to shareholders

 

Further highlighted details

  • Drilling Confirms Mineralisation Below High-Grade Surface: Click Here (30th April 2021)
  • Sale of Zaruma Mine & Portovelo Process Plant for US$15m: Click Here (15th April 2021)
  • Copper Duke Geophysics Define Multiple Porphyry Targets: Click Here (2nd March 2021)

Enquiries:

Laurence Marsland
Managing Director
Titan Minerals
+61 8 6555 2950
[email protected]

Andrew Krelle
Financial Adviser
Bacchus Capital Advisers Ltd
+44 (0) 795 636 2903
[email protected]

Christine Wootliff
Investor Relations
121 Group
+852 3628 2420
[email protected]

Release – Genprex (GNPX) – Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer


Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

 

Acclaim-2 Clinical Trial Combines REQORSA™ immunogene therapy with Merck & Co’s Keytruda®

Company Expects to Recruit Approximately 15 Sites Across the United States

AUSTIN, Texas — (May 4, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is pleased to announce it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (NSCLC).

Acclaim-2 is an open-label, multi-center Phase 1/2 clinical trial that combines Genprex’s lead drug candidate, REQORSA™ immunogene therapy, with Merck & Co, Inc’s Keytruda in patients with late-stage NSCLC who are low expressors (1% to 49%) of the protein programmed death-ligand 1 (“PD-L1”).

“Our clinical team remains focused on engaging with leading clinical investigators and esteemed research institutions in order to further our mission of bringing hope to lung cancer patients who are in need of new treatment options,” said Rodney Varner, President and Chief Executive Officer of Genprex. “We look forward to selecting the most optimal study sites, which will help to further fuel the success of our clinical trials.”

The Company plans to conduct the Acclaim-2 clinical trial in approximately 15 sites with about 150 patients in an adaptive Phase 1/2 design. The final protocol is subject to change based on input from investigators.Additional information on the Acclaim-2 clinical trial will be posted on ClinicalTrials.gov.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with TagrissoFor more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses. 

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
[email protected]

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
[email protected]

Release – Comtech Telecommunications (CMTL) – Awarded $6.5 Million of Funding for Cyber Training Solutions


Comtech Telecommunications Corp. Awarded $6.5 Million of Funding for Cyber Training Solutions

 

MELVILLE, N.Y.–(BUSINESS WIRE)–May 4, 2021– 
May 4, 2021— 
Comtech Telecommunications Corp. (NASDAQ: CMTL), a world leader in secure wireless communications technologies, announced today, that during its third quarter of fiscal 2021, its Government Solutions segment was awarded an additional 
$6.5 million of funding from the Federal Government for its Joint Cyber Analysis Course (“JCAC”) Training solutions. The contract has been funded 
$76.3 million to date.

“Our Cyber Training team continues to provide dynamic, high-quality Cyber Security training to the DoD,” said  Fred Kornberg, Chairman of the Board and Chief Executive Officer of 
Comtech Telecommunications Corp. “This funding demonstrates the Government’s continued confidence in Comtech’s cyber products and services, as well as in preparing 
DoD personnel for cyber challenges today and beyond.”

Comtech Telecommunications Corp. is a leader in the global communications market headquartered in 
Melville, New York. With a passion for customer success, 
Comtech designs, produces and markets advanced secure wireless solutions to more than 1,000 customers in more than 100 countries. For more information, please visit www.comtechtel.com.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s 
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such 
Securities and Exchange Commission filings.

Media Contact:
Michael D. Porcelain, President and Chief Operating Officer

Comtech Telecommunications Corp.
631-962-7000
[email protected]

Source: 
Comtech Telecommunications Corp.

Release – electroCore Inc. (ECOR) – Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire (Non-Invasive Vagus Nerve Stimulator) for the Treatment of Post-Traumatic Headache


electroCore, Inc. Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire™ (Non-Invasive Vagus Nerve Stimulator) for the Treatment of Post-Traumatic Headache

 

ROCKAWAY, NJ
May 04, 2021 (GLOBE NEWSWIRE) — — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the 
U.S. Department of Veterans Affairs is starting an investigator-initiated study of the use of gammaCore SapphireTM non-invasive vagus nerve stimulation (nVNS) for the treatment of post-traumatic headache (PTH). PTH accounts for approximately 4% of all symptomatic headache disorders1 and is one of the most common consequences of mild traumatic brain injury (mTBI),2,3 also known as concussion. Estimates suggest that 69 million people per year experience a traumatic brain injury (TBI) worldwide.4 In addition, patients with PTH commonly suffer from comorbidities such as anxiety and depression,5 both of which are among the leading causes of disability worldwide.6

The study (GAP-PTH) is a randomized, multi-center, double-blind, parallel, sham-controlled trial enrolling up to 100 veterans and directed by the Veterans Health Administration’s 
Headache Center of Excellence (HCoE) at the 
West Haven VA Medical Center in 
West Haven, CT. PTH is a critical area of concern for the 
VA and it is estimated that more than 350,000 service members have headaches resulting from TBIs sustained in combat. PTH in veterans is most often caused by the kind of TBIs experienced during combat, including blast wave injuries

“PTH is one of the most common presentations among veterans who come to our 
VA Headache Centers of Excellence around 
the United States. Last year the 
Veterans Health Administration was caring for more than 140,000 veterans diagnosed with headache related to head trauma,” commented Dr. Jason Sico, National Director of the 
VA Headache Centers of Excellence Program and Associate Professor of Neurology (Headache Medicine and Vascular Neurology) and Internal Medicine (General Medicine) 
Yale School of Medicine.

“We have been using gammaCore nVNS successfully in veterans suffering from cluster headache and migraine at our center,” commented Dr.  Emmanuelle Schindler, Medical Director of the HCoE at 
VA Connecticut Healthcare System, Assistant Professor of Neurology at 
Yale School of Medicine, and primary investigator of the GAP-PTH study. “This will be among the first Randomized Controlled Trials (RCTs) for PTH and we look forward to demonstrating how gammaCore nVNS can help our veterans with PTH.”

“We appreciate the opportunity to work with  Dr. SchindlerDr. Sico and their team to evaluate the potential of gammaCore as an acute and/or preventive option for PTH” said  Eric Liebler, Senior Vice President of Neurology at electroCore, Inc. “gammaCore is being used across the 
Department of Veterans Affairs and 
Department of Defense for both cluster and migraine headache and we believe that the same mechanisms of action that support the efficacy of gammaCore in primary headaches could also provide relief to our servicemen, servicewomen, and veterans suffering from post-traumatic headache.”

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are for the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

  • gammaCore is contraindicated for patients with:
    • An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
    • A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
    • An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location
  • Safety and efficacy of gammaCore have not been evaluated in the following patients:
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric patients (younger than 12 years)
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the availability and impact of payer coverage, the potential of nVNS generally and gammaCore in particular to treat post-traumatic headache or traumatic brain injury and related disorders and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.


1 Seifert, T. D. & Evans, R. W. Posttraumatic headache: a review. Curr. Pain Headache Rep. 14, 292–298 (2010).
2 Nampiaparampil, D. E. Prevalence of chronic pain after traumatic brain injury: a systematic review. JAMA. 300, 711–719 (2008).
3 Mullally, W. J. Concussion. Am. J. Med. 130, 885–892 (2017).
4 Dewan, M. C. et al. Estimating the global incidence of traumatic brain injury. J. Neurosurg. 27, 1–18 (2018)
5 Minen, M. T., Boubour, A., Walia, H. & Barr,  W. Post-concussive syndrome: a focus on post- traumatic headache and related cognitive, psychiatric, and sleep issues. Curr. Neurol. Neurosci. Rep. 16, 100 (2016). A review that details the clinical characteristics and associated comorbidities of PTH.
6 GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. 
Lancet. 388, 1545–1602 (2016).


Investors:
Rich CockrellCG Capital
404-736-3838
[email protected]

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]

Release – ACCO Brands (ACCO) – Declares Quarterly Dividend


ACCO Brands Corporation Declares Quarterly Dividend

 

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that its board of directors has declared a quarterly cash dividend of $0.065 per share. The dividend will be paid on June 21, 2021, to stockholders of record as of the close of business on May 27, 2021.

About ACCO Brands Corporation

ACCO Brands Corporation is one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products. Our widely recognized brands include AT-A-GLANCE®, Barrilito®, Derwent®, Esselte®, Five Star®, Foroni®, GBC®, Hilroy®, Kensington®, Leitz®, Mead®, PowerA®, Quartet®, Rapid®, Rexel®, Swingline®, Tilibra®, Wilson Jones®, and many others. Our products are sold in more than 100 countries around the world. More information about ACCO Brands, the Home of Great Brands Built by Great People, can be found at www.accobrands.com.

Christine Hanneman
Investor Relations
(847) 796-4320

Julie McEwan
Media Relations
(937) 974-8162

Source: ACCO Brands Corporation

Release – Lineage Cell Therapeutics (LCTX) – To Report First Quarter 2021 Financial Results And Provide Business Update On May 13 2021

 


Lineage Cell Therapeutics To Report First Quarter 2021 Financial Results And Provide Business Update On May 13, 2021

 

CARLSBAD, Calif.–(BUSINESS WIRE)–May 4, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2021 financial and operating results on 
Thursday, May 13, 2021, following the close of the 
U.S. financial markets. Lineage management will also host a conference call and webcast on 
Thursday, May 13, 2021, at 
4:30 p.m. Eastern Time/
1:30 p.m. Pacific Time to discuss its first quarter 2021 financial and operating results and to provide a business update.

Interested parties may access the conference call by dialing (866) 888-8633 from the 
U.S. and 
Canada and (636) 812-6629 from elsewhere outside the 
U.S. and 
Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through 
May 21, 2021, by dialing (855) 859-2056 from the 
U.S. and 
Canada and (404) 537-3406 from elsewhere outside the 
U.S. and 
Canada and entering conference ID number 4996965. 

About Lineage Cell Therapeutics, Inc. 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
([email protected])
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
([email protected])
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or  David Schull
[email protected]
[email protected]
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Gray Television Inc. (GTN) – Leapfrogs Into The Super Broadcast League

Tuesday, May 04, 2021

Gray Television Inc. (GTN)
Leapfrogs Into The “Super” Broadcast League

Gray Television, Inc. operates as a television broadcast company in the United States. As of April 6, 2010, it operated 36 television stations in 30 markets, including 17 affiliated with CBS Inc.; 10 affiliated with the National Broadcasting Company, Inc.; 8 affiliated with the American Broadcasting Company (ABC); and 1 affiliated with FOX Entertainment Group, Inc. (FOX). The company also operated 39 digital second channels comprising 1 affiliated with ABC, 4 affiliated with FOX, 7 affiliated with CW Network, LLC, 18 affiliated with Twentieth Television, Inc., 2 affiliated with Universal Sports Network, and 7 local news/weather channels. Gray Television, Inc. was founded in 1897 and is headquartered in Atlanta, Georgia.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Gains national scale.  The company will leap frog into the big leagues covering 36% of US TV households, without the UHF discount rule, upon the planned purchase of Meredith’s TV group. The purchase price of $2.7 billion represents 7.9 times blended 2019/2020 cash flow, after synergies, a reasonable price, in our view. The deal is expected to close year end 2021.

    Move viewed favorably.  The Meredith stations dovetail nicely with the company’s existing stations and creates significant scale in many States, including Nevada, Arizona, Missouri, positioning it well for Political advertising. The company plans to sell only one overlap station in Flint, MI, to expedite regulatory approval, which is expected …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Avivagen (VIVXF)(VIV:CA) – Announces Recurring Order for OxC-beta Livestock


Avivagen Announces Recurring Order for OxC-beta™ Livestock

 

• Largest purchase amount and longest duration purchase to-date
• Four tonne per month order secured
• Order follows five successful OxC-beta™ Livestock commercial trials conducted with various species over the past six months

Ottawa, ON / Business Wire/ May 3, 2021 / Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that Meyenberg International Group, Avivagen’s consultant in Mexico, has entered into a contract which secures a four tonne per month recurring order for OxC-beta™ Livestock in Mexico.

The contract, which is 18 months from signing and includes an order for 500 Kgs delivered April 30th, is a commitment to purchase a minimum of four tonnes monthly, commencing in July, 2021 and ending October, 2022

“As we continue to see successful commercial trials conclude in those jurisdictions where OxC-beta™ Livestock is approved, we anticipate increased demand to follow, as has recently been demonstrated in Mexico and Thailand,” said Kym Anthony, Chief Executive Officer of Avivagen.  “With numerous other commercial trials currently underway and nearing completion, it is our belief that the continued success of such company conducted trials will help to accelerate the adoption and use of OxC-beta™ Livestock in approved jurisdictions and beyond. It is our belief that OxC-beta™ Livestock, once started by a customer, becomes core to their continued operations and will drive recurring orders for years to come.”

Meyenberg International Group
With a client base across North America and a well-earned reputation for enabling rapid growth for clients expanding into LATAM, Meyenberg’s experience in Mexico has enabled Avivagen to quickly establish and grow sales in the country since securing regulatory approval in August 2019.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim”, anticipate”, appear”, believe”, consider”, could”, estimate”, expect”, if”, intend”, goal”, hope”, likely”, may”, plan”, possibly”, potentially”, pursue”, seem”, should”, whether”, will”, would” and similar expressions. Statements set out in this news release relating to the recurring nature of the orders under the contract described above, the anticipated date of fulfillment for the order described,  Avivagen’s expectation that the customer in question will live up to its contractual commitment to purchase product monthly, anticipated increase in demand for Avivagen’s products,  Avivagen’s expectation that commercial trials currently underway will be completed and yield positive results, the anticipated impact of the results of such trials on demand for product, expectations as to the recurring and long term nature of a customer’s purchases once they begin using Avivagen’s products and  the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the order described may not result in new orders for Avivagens products,  the customer plans may change due to many reasons, timing of fulfillment of the order may be delayed beyond current expectation for a number of reasons which would push fulfillment and recognition of revenues for this order into a future quarter or cause such order to be cancelled, the parties to the contract described may not live up to their contractual commitments and/or may agree to amend such contract to reduce the commitments described above, demand for Avivagens products may not continue to grow and could decline,  commercial trials may not be completed and, if completed, may not yield results that are positive or which lead to additional demand for Avivagen’s products, except as otherwise stated, customers are under no obligation to continue using Avivagen’s products and Avivagens products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications, including human applications, and may not be widely accepted as a replacement for antibiotics in livestock feeds, , in each case due to many factors, many of which are outside of Avivagens control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagens most recent managements discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: [email protected]

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

Release – TAAL Distributed Information Technologies (TAALF) – Files 2020 Fiscal Year-End Financial Results And Provides Operational Guidance For 2021


TAAL Files 2020 Fiscal Year-End Financial Results And Provides Operational Guidance For 2021

 

Vancouver, British Columbia; April 30, 2021 – TAAL Distributed Information Technologies Inc. (CSE:TAAL | FWB:9SQ1 | OTC:TAALF) (“TAAL” or the “Company”), a vertically integrated blockchain infrastructure and service provider for enterprise, announced today its financial results and Management Discussion and Analysis for the fiscal year ended December 31, 2020. These filings are available for review on the Company’s SEDAR profile at www.sedar.com and on the Company’s website at www.taal.com. All financial information in this press release is reported in Canadian dollars unless otherwise indicated.
 

SUBSEQUENT TO YEAR-END

 

  • As of March 31, 2021, TAAL had approximately 74,000 BitcoinSV (“BSV”) in treasury
  • Based on current network conditions, TAAL anticipates winning at least 30 blocks per day attributable to TAAL
    • Each block currently paying 6.25 BitcoinSV as a reward
    • TAAL pool averaged 45 blocks a day in Q1 2021
  • On March 18th, TAAL closed an oversubscribed prospectus offering for aggregate gross proceeds of approximately $40 Million
  • On March 13th, TAAL processed a world record 638MB block on the BSV blockchain network
  • Hashing operations commenced in Canada in Q1 of 2021.

 

2020 OVERVIEW

 
2020 was a year of groundwork for TAAL in transitioning its business towards the goal of becoming a world leader in blockchain infrastructure and transaction processing.

The Company purchased new blockchain computers, which are anticipated to help the Company reach its 2021 goal of 400 petahash, owned and controlled by TAAL, on the BSV blockchain network once fully deployed.

Also, in 2020, TAAL expanded its enterprise blockchain infrastructure services with its acquisition of WhatsOnChain. WhatsOnChain owns proprietary BitcoinSV blockchain explorer technology developed by its founders, who created the first-ever BSV block explorer to provide data in an easy and user-friendly manner.

Q3 2020 saw a new TAAL office in Zug, Switzerland, and key hires in c-suite and senior management roles. In connection with the Zug office opening, TAAL onboarded several key new hires to expand the Company’s operations, including a new President, Chief Operating Officer, Chief Technology Officer, Chief Compliance Officer. In addition, Q4 2020 saw the election of two new members to its Board of Directors, and  Mr. Stefan Matthews, the Chairman of the Company’s board of directors, took on the Chief Executive Officer position and is now serving as Executive Chairman and Chief Executive Officer.

Stefan Matthews, TAAL’s CEO and Executive Chairman, commented that

“2020 was a year of transition for TAAL. Despite the challenges of the global pandemic, 2020 marked multiple and significant milestones for TAAL in building the infrastructure, capacity, and global expertise to enable us to execute our strategic plan. We see evidence of Blockchain technology moving significantly closer to mass adoption. Our infrastructure and product innovations, built on the BitcoinSV protocol with its scalability and ultra-low transaction fee advantages, position us to enable enterprise transformation across global markets using this technology. I congratulate our entire team on their hard work and commitment towards preparing TAAL to be a  global blockchain leader.”

 

NEW WEBSITE ANNOUNCEMENT 2021

 
TAAL recently launched its newly designed website, designed to enhance clients’ online experience and provide an easier way for investors to learn about TAAL (taal.com).
 

ABOUT TAAL DISTRIBUTED INFORMATION TECHNOLOGIES INC.

 
TAAL Distributed Information Technologies Inc. delivers value-added blockchain services, providing professional-grade, highly scalable blockchain infrastructure and transactional platforms to support businesses building solutions and applications upon the BitcoinSV platform, and developing, operating, and managing distributed computing systems for enterprise users.

Visit TAAL online at www.taal.com

The CSE, nor its Regulation Services Provider, accepts no responsibility for the adequacy or accuracy of this release.
 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

 
Certain statements included in this news release constitute “forward-looking information” as defined under applicable Canadian securities legislation. The words “will”, “intends”, “expects” and similar expressions are intended to identify forward-looking information, although not all forward-looking information will contain these identifying words. Specific forward-looking information contained in this news release includes but is not limited to statements regarding: the growth of TAAL’s treasury through, among other things, BSV hashing activities; TAAL Pool’s anticipated hashing activity; TAAL’s future computing power and capacity; and TAAL’s business and strategic plans. These statements are based on factors and assumptions related to historical trends, current conditions and expected future developments. Since forward-looking information relates to future events and conditions, by its very nature it requires making assumptions and involves inherent risks and uncertainties. TAAL cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from expectations. Material risk factors include the future acceptance of Bitcoin SV and other digital assets and risks related to information processing using those platforms, the ability for TAAL to leverage intellectual property into viable income streams and other risks set out in TAAL’s Annual Information Form dated April 30, 2021 under the heading “Risk Factors” and elsewhere in TAAL’s continuous disclosure filings available on SEDAR at www.sedar.com. Given these risks, undue reliance should not be placed on the forward-looking information contained herein. Other than as required by law, TAAL undertakes no obligation to update any forward-looking information to reflect new information, subsequent or otherwise.
 

FOR FURTHER INFORMATION CONTACT:

 
Matt Whitcomb, Investor Relations, [email protected] 604-260-6142

Stefan Matthews, CEO & Executive Chairman, [email protected]

Chris Naprawa, President, [email protected]